Financials
Financial year 2025
CFA Pharma from Ieper, company number BE0428715650, closed financial year 2025 with a result of € 6,743 after tax. For that financial year CFA Pharma recorded a gross margin of € 52,159 and equity of € 153,937. Compared with financial year 2024, the result moved from € 26,656 to € 6,743. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.
€ 153,937
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 6,743
▼ 75% vs 2024
Profit after tax over the fiscal year.
€ 6,105
▼ 21% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 6,000 paid out
89 % of the profit went to the shareholders, the rest stayed in the company.
Debts at end 2025
€ 295,224
▲ 65% vs 2024
€ 38,753 is repaid this year. At this pace the long-term loan is gone in ≈ 8 years.
€ 45,587
▲ 20% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 4,539
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 49,871 | € 21,370 | € 52,742 | € 52,159 | ▼ 1% |
| Profit after taxes | € 27,199 | € 645 | € 26,656 | € 6,743 | ▼ 75% |
| Equity | € 139,545 | € 136,539 | € 153,194 | € 153,937 | |
| Total debts | € 107,481 | € 335,057 | € 236,553 | € 371,349 | ▲ 57% |
| Cash | € 42,952 | € 123,506 | € 7,679 | € 6,105 | ▼ 21% |
| Land & buildings | - | - | - | € 136,463 | |
| Retained profit | € 111,545 | € 108,539 | € 125,194 | € 125,937 | ▲ 1% |
| Dividend | € 17,100 | € 3,651 | € 10,000 | € 6,000 | ▼ 40% |
| Bank debt | € 103,561 | € 205,057 | € 178,445 | € 295,224 | ▲ 65% |
| Balance sheet total | € 247,026 | € 471,596 | € 389,747 | € 525,286 | ▲ 35% |
Key figures of CFA Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to CFA Pharma?
What happened at CFA Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 6,743 (▼ 75% vs 2024). filed late Source: NBB ↗
- MILDRO SA became a director. NBB
- Anne-Sophie Bonte became a director. NBB
- New establishment in Ieper. KBO
- Start of the company according to the CBE. KBO
In short
From € 27,199 profit in 2022 to € 6,743 profit in 2025.
Paid € 14,059 in corporate taxes since 2022.
Best year ever: 2022, with € 27,199 profit.
Paid out € 36,751 in dividends to the owners in total.
Management
Behind CFA Pharma are MILDRO SA and Anne-Sophie Bonte. The same people are also behind Apotheek Bonte.
Directors
According to the 2025 annual accounts
since 2024
since 2024
Establishments
Establishment units
Physical locations of this company
Blauwepoortstraat 1
8902 Ieper
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0428.715.650
- VAT number
- BE 0428.715.650
- Registered office
- Blauwepoortstraat 1, 8902 Ieper
- Names & denominations
- CFA Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 24 March 1986
- Peppol
- Active · Active since 2 Jun 2026
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers